SEARCH

Current Edition

Biohaven

Pfizer to acquire Biohaven in $11.6B bet on biotech’s migraine drugs

Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a …

Continue Reading →
Biohaven

Pfizer buys into Biohaven’s fast-selling migraine medicine

Faced with breaking into markets led by larger companies, Biohaven turned to celebrity endorsements, Tiktok and racecar advertising to aggressively sell Nurtec ODT. Its digital-focused …

Continue Reading →
ABBVIE

Biohaven’s pipeline takes a hit as drug for rare neurological disease falls short in trial

Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …

Continue Reading →
Amgen

Amgen, Novartis’ closely watched migraine drug approved

Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments …

Continue Reading →